JP2022502434A5 - - Google Patents
Info
- Publication number
- JP2022502434A5 JP2022502434A5 JP2021517299A JP2021517299A JP2022502434A5 JP 2022502434 A5 JP2022502434 A5 JP 2022502434A5 JP 2021517299 A JP2021517299 A JP 2021517299A JP 2021517299 A JP2021517299 A JP 2021517299A JP 2022502434 A5 JP2022502434 A5 JP 2022502434A5
- Authority
- JP
- Japan
- Prior art keywords
- antagonist
- weeks
- sfrp2
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862737155P | 2018-09-27 | 2018-09-27 | |
| US62/737,155 | 2018-09-27 | ||
| PCT/US2019/053651 WO2020069439A1 (en) | 2018-09-27 | 2019-09-27 | Pharmaceutical combination for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022502434A JP2022502434A (ja) | 2022-01-11 |
| JP2022502434A5 true JP2022502434A5 (https=) | 2022-10-05 |
| JP7451506B2 JP7451506B2 (ja) | 2024-03-18 |
Family
ID=69953118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517299A Active JP7451506B2 (ja) | 2018-09-27 | 2019-09-27 | がんの治療用の薬学的組合せ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210395351A1 (https=) |
| EP (1) | EP3856784A4 (https=) |
| JP (1) | JP7451506B2 (https=) |
| KR (1) | KR102947706B1 (https=) |
| CN (2) | CN119818670A (https=) |
| AU (1) | AU2019351267A1 (https=) |
| BR (1) | BR112021005525A2 (https=) |
| CA (1) | CA3114173A1 (https=) |
| IL (1) | IL281782A (https=) |
| MX (1) | MX2021003274A (https=) |
| SG (1) | SG11202102865WA (https=) |
| WO (1) | WO2020069439A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114269376A (zh) * | 2019-05-03 | 2022-04-01 | 豪夫迈·罗氏有限公司 | 用抗pd-l1抗体治疗癌症的方法 |
| WO2025199292A1 (en) * | 2024-03-21 | 2025-09-25 | Musc Foundation For Research Development | A humanized monoclonal antibody to sfrp2 for tumor associated macrophage reduction and polarization in cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011523551A (ja) * | 2008-05-15 | 2011-08-18 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 血管形成の調節の新規ターゲット |
| WO2011119524A1 (en) * | 2010-03-22 | 2011-09-29 | The University Of North Carolina At Chapel Hill | Novel targets for regulation of angiogenesis |
| US9759725B2 (en) * | 2012-08-02 | 2017-09-12 | Fred Hutchinson Cancer Research Center | Treatment-induced damage to the tumor micro-environment promotes cancer therapy resistance through extracellular proteins |
| EA037548B1 (ru) * | 2015-06-24 | 2021-04-12 | Янссен Байотек, Инк. | Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38 |
| JP2018518526A (ja) * | 2015-06-25 | 2018-07-12 | アドバンスド アクセレレーター アプリケーションズ | ソマトスタチン受容体を過剰発現する神経内分泌腫瘍を処置する方法 |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| US10273281B2 (en) | 2015-11-02 | 2019-04-30 | Five Prime Therapeutics, Inc. | CD80 extracellular domain polypeptides and their use in cancer treatment |
| ES3034233T3 (en) * | 2016-01-22 | 2025-08-14 | MabQuest SA | Non-blocking pd1 specific antibodies |
| EP3582811B1 (en) | 2017-02-14 | 2024-07-10 | Novartis AG | Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination |
-
2019
- 2019-09-27 CN CN202411827485.1A patent/CN119818670A/zh active Pending
- 2019-09-27 WO PCT/US2019/053651 patent/WO2020069439A1/en not_active Ceased
- 2019-09-27 KR KR1020217012004A patent/KR102947706B1/ko active Active
- 2019-09-27 AU AU2019351267A patent/AU2019351267A1/en active Pending
- 2019-09-27 US US17/279,857 patent/US20210395351A1/en active Pending
- 2019-09-27 SG SG11202102865WA patent/SG11202102865WA/en unknown
- 2019-09-27 CN CN201980076608.3A patent/CN113454114B/zh active Active
- 2019-09-27 MX MX2021003274A patent/MX2021003274A/es unknown
- 2019-09-27 CA CA3114173A patent/CA3114173A1/en active Pending
- 2019-09-27 JP JP2021517299A patent/JP7451506B2/ja active Active
- 2019-09-27 BR BR112021005525-8A patent/BR112021005525A2/pt unknown
- 2019-09-27 EP EP19866195.1A patent/EP3856784A4/en active Pending
-
2021
- 2021-03-24 IL IL281782A patent/IL281782A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69932600T2 (de) | Zusammensetzungen und verfahren zur behandlung von tumoren | |
| Lewis Phillips et al. | Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis | |
| US6333348B1 (en) | Use of docetaxel for treating cancers | |
| DE60128208T2 (de) | Verfahren zum Behandeln von Krebs mit Anti-Neurotrophin-Mitteln | |
| US20020076408A1 (en) | Combination radiation therapy and chemotherapy in conjunction with administration of growth factor receptor antibody | |
| US20060171946A1 (en) | Compositions and methods for the treatment and prevention of hyperproliferative diseases | |
| MXPA02011194A (es) | Inhibidores de aromatasa y anticuerpos anti-her2 monoclonales como agentes antitumorales. | |
| CN109153724A (zh) | 通过施用pd-1抑制剂治疗皮肤癌的方法 | |
| WO2019096194A1 (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| JP2009120583A (ja) | 上皮成長因子受容体アンタゴニストによる難治性ヒト腫瘍の処理 | |
| DE60316106T2 (de) | Gemeinsamer lymphatischer endothel- und gefässendothel-rezeptor-1 (clever-1) und seine verwendung | |
| WO2021182573A1 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| JP2025060639A (ja) | Ｐｄ－１／ｐｄ－ｌ１シグナル伝達阻害剤に不応答性のがんの処置方法および医薬 | |
| CN109476733A (zh) | 使用il-17拮抗剂治疗新发斑块型银屑病的方法 | |
| DE69837322T2 (de) | Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln | |
| JP2022502434A5 (https=) | ||
| CN113318226A (zh) | 抗pd-l1抗体联合放射性射线治疗肺癌的方法 | |
| JP2023537115A5 (https=) | ||
| KR20240168479A (ko) | 건선 치료 방법 | |
| US20230172882A1 (en) | Method For Treating Pancreatic Cancer | |
| EP4115902A1 (en) | Combined use of ctb006 and ponatinib | |
| CN118076377A (zh) | 人类表皮生长因子第二型受体疫苗组成物 | |
| Gaustad et al. | Properdistatin inhibits angiogenesis and improves vascular function in human melanoma xenografts with low thrombospondin-1 expression | |
| Zhang et al. | A phase I study of Hemay022, an irreversible dual EGFR/HER2 tyrosine kinase inhibitor in Chinese patients with HER2-positive advanced breast cancer | |
| WO2021182572A1 (ja) | 癌の治療及び／又は予防のための医薬品 |